Mannkind (MNKD) Notes Payables (2012 - 2025)

Mannkind (MNKD) posted quarterly Notes Payables of $36.3 million for Q4 2025, little changed quarter-over-quarter from $36.2 million in Q3 2025.

Mannkind (MNKD) Notes Payables (2012 - 2025) Analysis & Trends

Mannkind (MNKD) has reported Notes Payables for 8 consecutive years, with $36.3 million the latest figure, recorded in Q4 2025.

In Q4 2025, Notes Payables changed N/A year-over-year to $36.3 million; the TTM figure through Dec 2025 stood at $36.3 million (changed N/A YoY), while the FY2025 annual figure was $36.3 million, changed N/A from the prior year.
Notes Payables held at $36.3 million in Q4 2025 per MNKD's latest filing, from $36.2 million in the prior quarter.
Across five years, Notes Payables topped out at $36.3 million in Q4 2025 and bottomed at $36.1 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Mannkind	1.19 Bn	1.08 Bn	94.97 Mn

Download Data